Alzheimer's disease (AD) refers to a type of neurologic condition, which causes the brain to shrink and brain cells to die over time. AD is the most frequent form of dementia in which a progressive loss in social, cognitive and behavioral abilities occurs that impairs a person's capacity to operate independently. The primary symptom of AD is forgetting recent events or discussions. A person with AD will have severe memory impairment, while losing the capacity to perform daily tasks, as the disease progress. Drug development for AD relies heavily on biomarkers and they can also be used to facilitate diagnosis, safety monitoring, demonstrating target engagement and supporting the modification of disease. AD is incurable due to its multifactorial and complex nature. Biomarkers aid in characterizing the baseline state, a therapy response or a disease process. This book is compiled in such a manner, that it will provide in-depth knowledge about the assessment and management of Alzheimer's disease. It presents researches and studies performed by experts across the globe.